CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net Cash Provided by (Used in) Operating Activities
Net (loss)	$ (1,539,637)	$ (1,319,840)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and Amortization	17,404	7,556
Changes in assets and liabilities:
Prepaid expenses and other receivables	224,392	(407,805)
Prepayment to related party for clinical trials	249,459	0
Accounts payable	(31,279)	117,226
Accrued expenses	(129,704)	170,000
Net cash (used in) provided by in operating activities	$ (1,209,365)	(1,432,863)
Cash Flows from Investing Activities:
Decrease in restricted cash		85,462
Purchase of intangible assets	$ (78,197)	(76,745)
Purchase of property and equipment	(9,367)	(15,457)
Net cash Provided by used in investing Activities	(87,564)	(6,740)
Cash Flows From Financing Activities:
Net proceeds from issuance of common stock	10,000,000	0
Net advances from related party	299,434	0
Net cash provided by financing activities	10,299,434	0
Net increase/(decrease) in cash	9,002,505	(1,439,603)
Effect of exchange rate changes on cash	46,711	(78,789)
Cash at beginning of period	354,749	1,873,141
Cash at end of period	$ 9,403,965	$ 354,749